![]() |
市場調查報告書
商品編碼
1448304
全球乳癌診斷市場規模、佔有率和成長分析:按類型、應用和產品分類 - 產業預測(2024-2031)Global Breast Cancer Diagnostics Market Size, Share, Growth Analysis, By Type(Imaging, Biopsy), By Application(Screening, Diagnostic and Predictive), By Product(Hospital, Homecare) - Industry Forecast 2024-2031 |
2022年全球乳癌診斷市場規模將為195.1億美元,從2023年的217.5億美元擴大到2031年的519.7億美元,並將在預測期內(2024-2031年)持續成長,預計將以年複合成長率成長11.5%。
乳癌是影響世界各地女性的常見癌症,早期往往沒有明顯徵兆。為了應對這項挑戰,乳癌診斷市場正在專注於開發人工智慧技術。例如,Paragon Biosciences LLC 推出了 Qlarity Imaging LLC,以尋求 FDA核准其人工智慧系統,該系統可協助利用放射線診斷乳癌。透過利用人工智慧,該市場的公司旨在顯著改善醫療結果。人工智慧正在應用於多種類型的圖像,為醫院和付款人提供具有成本效益的解決方案。這些公司正在投資具有易於使用的介面和機器學習功能的人工智慧系統,這些系統正在改變乳癌的診斷和治療方式。全球私人診斷中心的成長是由於對診斷影像的需求不斷成長以及公立醫院的壓力所推動的,而公立醫院的診斷影像選擇可能有限。FUJIFILM與 Dr. Kutty's Healthcare 合作,在印度班加羅爾開設了 NURA 癌症篩檢中心,解決了這個問題。在新興國家,由於成本高且預算有限,醫院在購買診斷影像設備方面面臨挑戰。一些醫院選擇翻新產品作為更實惠的選擇,價格約為原始成本的 40% 至 60%。看到翻新產品的受歡迎,西門子、GE醫療和飛利浦等產業巨頭紛紛推出了推廣其使用的計畫。這些計劃,例如西門子的醫療卓越計劃和通用電氣醫療集團的金印計劃,以較低的價格提供高品質的診斷成像設備,幫助醫院滿足日益成長的診斷服務需求。
Global Breast Cancer Diagnostics Market size was valued at USD 19.51 billion in 2022 and is poised to grow from USD 21.75 billion in 2023 to USD 51.97 billion by 2031, growing at a CAGR of 11.5% in the forecast period (2024-2031).
Breast cancer is a common type of cancer that affects women worldwide, often showing no clear signs in its early stages. To address this challenge, the breast cancer diagnostics market is focusing on developing AI technologies. Paragon Biosciences LLC, for instance, introduced Qlarity Imaging LLC, aiming to get FDA approval for an AI system to help diagnose breast cancer using radiology. By using AI, companies in this market aim to improve medical outcomes significantly. AI is being used in various types of images, offering hospitals and payers cost-effective solutions. These companies are investing in AI systems with easy-to-use interfaces and machine learning capabilities, changing how breast cancer is diagnosed and cared for. The rise in private diagnostic centers globally is driven by the increasing demand for diagnostic imaging and the pressure on public hospitals, which may have limited imaging options. FUJIFILM Corporation addressed this by launching NURA, a cancer screening center in Bangalore, India, in collaboration with Dr. Kutty's Healthcare. In developing countries, hospitals face challenges in getting diagnostic imaging equipment due to high costs and limited budgets. Some hospitals choose refurbished equipment as a more affordable option, priced at about 40% to 60% of the original cost. Seeing the popularity of refurbished devices, industry leaders like Siemens, GE Healthcare, and Philips have started programs to promote their use. These programs, such as Siemens' Medical Proven Excellence Program and GE Healthcare's Gold Seal Program, offer hospitals quality imaging equipment at lower costs, helping them meet the increasing demand for diagnostic services.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Breast Cancer Diagnostic Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Breast Cancer Diagnostic Market Segmental Analysis
Global Breast Cancer Diagnostic Market is segmented on the basis of application end use and region. By application, the market is segmented into handlings, assembling & disassembling, welding & soldering, clean room, dispensing, processing, others. By end use, market is segmented into automotive, electrical, metal machinery, chemical, rubber & plastics, food, others. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Drivers of the Global Breast Cancer Diagnostic Market
New technologies like advanced imaging methods, molecular diagnostics, and biomarker tests have greatly enhanced how breast cancer is detected and diagnosed. These innovations are leading to the use of more advanced diagnostic tools and helping the market grow.
Restraints in the Global Breast Cancer Diagnostic Market
Liquid biopsies, which involve the analysis of circulating tumor cells and cell-free DNA in blood samples, are gaining traction as non-invasive diagnostic tools for breast cancer. These tests offer potential for early detection and monitoring treatment response.
Market Trends of the Global Breast Cancer Diagnostic Market
Liquid biopsies, which analyze circulating tumor cells and cell-free DNA in blood samples, are becoming more popular as non-invasive ways to diagnose breast cancer. These tests have the potential to find cancer early and keep track of how well treatment is working.